CSL (ASX: CSL) — Perfil da empresa, notícias e dados financeiros
CSL is a global biotechnology company headquartered in Melbourne, Australia, specializing in rare and serious diseases, influenza vaccines, and iron deficiency therapies.
CSL
CSL is a global biotechnology company headquartered in Melbourne, Australia, specializing in rare and serious diseases, influenza vaccines, and iron deficiency therapies. The company operates through three principal business units: CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring produces plasma-derived and recombinant biotherapies for bleeding disorders, immunodeficiencies, and hereditary angioedema. CSL Seqirus manufactures seasonal and pandemic influenza vaccines using cell-based and egg-based technologies. CSL Vifor provides intravenous iron therapies and pharmaceutical treatments for nephrology and renal conditions. The company operates plasma collection centers across North America and Europe and maintains major manufacturing facilities in Australia, the United States, Switzerland, the United Kingdom, and Germany.
Resumo
Operações
Produtos e/ou serviços de CSL
- Plasma-Derived Therapies: Processing human plasma to manufacture immunoglobulins and albumin for treating primary immunodeficiencies, autoimmune conditions, critical care requirements, and neurological disorders across global markets. These therapies support patients in hospital, clinical, and home care environments worldwide.
- Recombinant & Coagulation Factors: Manufacturing recombinant and plasma-derived clotting factor therapies to manage and control bleeding in patients with hemophilia A, hemophilia B, von Willebrand disease, and other rare genetic bleeding disorders across global clinical care facilities.
- Influenza Vaccines: Producing cell-based, egg-based, and adjuvanted seasonal influenza vaccines, along with maintaining pandemic influenza response preparedness and fill-finish manufacturing sites in Australia, the United States, and the United Kingdom for global public health programs.
- Iron Deficiency Treatments: Formulating and distributing intravenous iron replacement products, including ferric carboxymaltose and iron sucrose, to treat iron deficiency anemia across nephrology, gastroenterology, cardiology, gynecology, and blood management clinical applications worldwide.
- Nephrology & Renal Care: Developing and marketing therapeutic solutions for chronic kidney disease, hyperkalemia, vascular calcification, and rare renal diseases, servicing patients undergoing pre-dialysis management and end-stage renal disease care across international clinical networks.
- Plasma Collection Operations: Operating a global network of over three hundred specialized plasma donation centers in the United States, Europe, and Australia, providing high-quality raw plasma needed to manufacture essential plasma-derived biopharmaceutical products.
equipe executiva do CSL
- Gordon NaylorCEO, MD & Executive Director
- Ken LimChief Financial Officer
- Mary OatesExecutive VP & COO
- Michelle ReesHead of Investor Relations
- Gregory BossExecutive VP of Legal & Group General Counsel
- Amy Van BurenChief People Officer
- William MezzanotteChief Medical Officer, Executive VP and Head of Research & Development
- Stephen MarlowExecutive VP & GM of CSL Plasma
- Mark HillChief Digital Information Officer & Executive VP
- Herve GisserotExecutive VP of Business Development & Enterprise Alliance Management
Últimas notícias sobre a CSL
CSL chairman to step down in March 2027
AustraliaCSL appoints Deborah Waterhouse as new CEO
AustraliaCSL signs US$355 million deal with Alentis
AustraliaCSL acknowledges shareholder frustration after $3.7B loss
AustraliaCSL enters U.S. agreements on pricing and expansion
AustraliaCSL reports US$2.6B full year loss
Australia
Comunicados recentes
O que a CSL (CSL) comunicou ao mercado, do mais recente para o mais antigo.
- Update on U.S. Plasma Collection Network
- CSL prices US$1.5 billion in Corporate Bonds
- CSL enters exclusive agreement with Alentis TherapeuticsFato relevante
Histórico de dividendos
Dividendos por ação pagos pela CSL, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2027(até o momento) | A$2.2772 | — | — | A$3.5272 |
| FY2026 | — | A$1.8098 | — | A$6.2098 |
| FY2025 | — | — | — | A$4.0000 |
| FY2024 | — | — | — | A$3.4000 |
| FY2023 | — | — | — | A$3.0000 |
Principais indicadores financeiros
Resultados divulgados pela CSL, em USD.
- Cap. de mercado
- 94,8 bi
- Receita (TTM)
- 15,8 bi
- P/L
- —
- LPA (diluído, TTM)
- -7.9
- Dividend yield
- 1.5%
- Margem de lucro
- -16.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 15,7 bi | 4 bi | -2,6 bi | |
| 15,4 bi | 3 bi | 3 bi | |
| 14,7 bi | 2,8 bi | 2,6 bi | |
| 13,2 bi | 2,1 bi | 2,2 bi |